Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | GLA | P06280 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.39 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591161 | 0.94 | KDM4E (0.49) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1694818 | 0.92 | KDM4E (0.48) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1694465 | 0.74 | KDM4E (0.62) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL1694956 | 0.73 | KDM4E (0.61) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL8401180 | 0.73 | GAA (0.56) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL2593981 | 0.72 | KDM4E (0.60) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL2587156 | 0.72 | KDM4E (0.57) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL2587537 | 0.70 | KDM4E (0.71) | KDM4EALDH1A1HPGDGLAGAA | |
| SCHEMBL14917598 | 0.70 | JAK2 (0.39) | KDM4EGAAJAK2JAK1JAK3 | |
| SCHEMBL1694829 | 0.70 | KDM4E (0.38) | KDM4EALDH1A1GAAJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| EP-2755962-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245016-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885HPGD 375/4885 |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | KDM4E 43/4885ALDH1A1 1092/4885HPGD 2177/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | KDM4E 682/4885ALDH1A1 114/4885HPGD 356/4885 |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | KDM4E 43/4885ALDH1A1 1092/4885HPGD 2177/4885 |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | EZH2, EZH1, BMI1 | KDM4E 43/4885ALDH1A1 1092/4885HPGD 2177/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1253/4885ALDH1A1 45/4885HPGD 403/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | KDM4E 1312/4885ALDH1A1 38/4885HPGD 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.